Status:
COMPLETED
Regorafenib in Taiwan Metastatic Colorectal Cancer (mCRC) Patients
Lead Sponsor:
Taipei Veterans General Hospital, Taiwan
Collaborating Sponsors:
Chang Gung Memorial Hospital
Koo Foundation Sun Yat-Sen Cancer Center
Conditions:
Metastatic Colorectal Cancer
Eligibility:
All Genders
20+ years
Brief Summary
Regorafenib is currently the standard of care for refractory mCRC patients. Pivotal studies of regorafenib have proven the efficacy and safety, with a 28-day cycle (21 days on, 7 days off) and 160 mg ...
Eligibility Criteria
Inclusion
- mCRC patients who received at least one dose of regorafenib treatment
Exclusion
- \<=20 y/o
- Patients who did not receive regorafenib treatment will be excluded from the analysis
- Patients with incomplete medical records that are deemed ineligible for analysis by investigator
Key Trial Info
Start Date :
February 11 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 8 2020
Estimated Enrollment :
716 Patients enrolled
Trial Details
Trial ID
NCT03829852
Start Date
February 11 2019
End Date
December 8 2020
Last Update
July 23 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Taipei Veterans General Hospital
Taipei, Taiwan